WGS (GeneDx Holdings) Operating Margin %: -13.32% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
65 GF Score
Price $90.32
GF Value $73.77
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GeneDx Holdings Operating Margin %?

GeneDx Holdings WGS +3.30% 65 Operating Margin % is -13.32% as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 65/100 and a GF Value™ of $73.77 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 202 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 63.37% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. GeneDx Holdings's Operating Income for the three months ended in Jun. 2026 was $-15.2 Mil. GeneDx Holdings's Revenue for the three months ended in Jun. 2026 was $114.4 Mil. Therefore, GeneDx Holdings's Operating Margin % for the quarter that ended in Jun. 2026 was -13.32%.

Good Sign:

GeneDx Holdings Corp operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for GeneDx Holdings's Operating Margin % or its related term are showing as below:

WGS' s Operating Margin % Range Over the Past 10 Years
Min: -210.25   Med: -84.02   Max: -3.06
Current: -12.96


WGS's Operating Margin % is ranked worse than
63.37% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.22 vs WGS: -12.96

GeneDx Holdings's 5-Year Average Operating Margin % Growth Rate was 57.20% per year.

GeneDx Holdings's Operating Income for the three months ended in Jun. 2026 was $-15.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-58.9 Mil.


GeneDx Holdings  (NAS:WGS) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


GeneDx Holdings Operating Margin % Related Terms


GeneDx Holdings Operating Margin % Historical Data

* Premium members only.

The historical data trend for GeneDx Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneDx Holdings Operating Margin % Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -210.25 -194.94 -84.02 -7.60 -3.06

GeneDx Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.80 -2.78 -11.77 -25.61 -13.32

WGS vs NEO, CDNA, PSNL: Operating Margin % Comparison

For the Diagnostics & Research subindustry, GeneDx Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneDx Holdings Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where GeneDx Holdings's Operating Margin % falls into.


WGS
65GF Score
GeneDx Holdings Corp WGS
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneDx Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

GeneDx Holdings's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-13.077 / 427.539
=-3.06 %

GeneDx Holdings's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-15.243 / 114.44
=-13.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -13.32% mean?
GeneDx Holdings (WGS) has a Operating Margin % of -13.32% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #128 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 63.4%.
Is GeneDx Holdings' Operating Margin % too high?
GeneDx Holdings' current Operating Margin % is -13.32%. Based on the distribution chart, GeneDx Holdings ranks #128 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, GeneDx Holdings has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Operating Margin % compare to NEO and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #128 out of 202 companies for Operating Margin %. This places GeneDx Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on GeneDx Holdings and its competitors. GeneDx Holdings's current Operating Margin % is -13.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $73.77, compared to a current price of $90.32 — trading 22.4% above its estimated fair value. The current Operating Margin % is -13.32%. GeneDx Holdings' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Operating Margin % is -13.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Operating Margin %: -13.32%
  • GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score

Get the complete analysis for WGS

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.32
Price
$73.77
GF Value